Successful antibody trial in HIV-infected individuals

A research team led by investigators of the Rockefeller University in New York and Prof Florian Klein, University Hospital Cologne and German Center for Infection Research (DZIF), has tested a new HIV neutralising antibody, called 10-1074, in humans. The results of the trial have just been published in Nature Medicine.

Over the last years, a new generation of HIV neutralizing antibodies was identified. "These antibodies are highly potent and are able to effectively neutralize a large number of different HIV strains. Therefore, they play an important role in the quest for and development of an HIV vaccine," explains Prof Klein. Additionally, in close collaboration with the Division of Infectious Diseases at the University Hospital Cologne (Prof Gerd Fätkenheuer) and scientists of the Rockefeller University in New York, Prof Klein's research group is investigating whether broadly neutralising antibodies can be used to treat HIV infection.

The just published trial investigates this approach. The broadly neutralizing antibody 10-1074 targets a specific structure (V3 loop) on the HIV envelope protein. In the study, the investigators show that the antibody was well tolerated and demonstrated favourable pharmacokinetic properties. Additionally, the antibody showed high antiviral activity in the participants with HIV infection. Furthermore, the team was able to specifically investigate the development of resistant HIV variants. "We performed a comprehensive HIV sequence analysis to investigate the dynamics and mechanisms HIV uses to escape the selection pressure by the antibody," says Dr Henning Gruell, one of the first authors of the current publication.

"This trial was only possible because of the intensive collaboration with the Rockefeller University and many other clinical and scientific partners," says Prof Klein, principal investigator in Germany and co-last author of the study. The scientists are planning further trials to investigate an antibody-mediated treatment approach in patients with HIV infection. Further trials have already been scheduled for spring.

Caskey, Schoofs, and Gruell et al.,
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Nature Medicine (2017) doi: 10.1038/nm.4268

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Pfizer receives FDA approval for SUTENT® (sunitini…

Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration has approved a new indication expanding the use of SUTENT® (sunitinib malate) to include...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]